{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:25Z","timestamp":1787032885568,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"DOI":"10.7759\/cureus.60980","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:14:42Z","timestamp":1716534882000},"source":"Crossref","is-referenced-by-count":9,"title":["The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Ruoning","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman NJ","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?. Br J Dermatol. 2020, 182:840-8. 10.1111\/bjd.18245","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15052","article-title":"Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: a 15-year nationwide population-based cohort study","volume":"46","author":"Jung KJ","year":"2019","unstructured":"Jung KJ, Kim TG, Lee JW, et al.. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: a 15-year nationwide population-based cohort study. J Dermatol. 2019, 46:859-66. 10.1111\/1346-8138.15052","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie A","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, et al.. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015, 74:326-32. 10.1136\/annrheumdis-2014-205675","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.952609","article-title":"Risk of myocardial infarction in psoriasis patients: a retrospective cohort study","volume":"26","author":"Wu JJ","year":"2015","unstructured":"Wu JJ, Choi YM, Bebchuk JD. Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat. 2015, 26:230-4. 10.3109\/09546634.2014.952609","journal-title":"J Dermatolog Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong EJ","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013, 2:e000062. 10.1161\/JAHA.113.000062","journal-title":"J Am Heart Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye JA","year":"2008","unstructured":"Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008, 159:895-902. 10.1111\/j.1365-2133.2008.08707.x","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.261784","article-title":"The IL-17A\/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment","volume":"110","author":"Butcher MJ","year":"2012","unstructured":"Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A\/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res. 2012, 110:675-87. 10.1161\/CIRCRESAHA.111.261784","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel C","year":"2009","unstructured":"Erbel C, Chen L, Bea F, et al.. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009, 183:8167-75. 10.4049\/jimmunol.0901126","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000116","article-title":"A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice","volume":"185","author":"Gao Q","year":"2010","unstructured":"Gao Q, Jiang Y, Ma T, et al.. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010, 185:5820-7. 10.4049\/jimmunol.1000116","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.924886","article-title":"Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice","volume":"121","author":"Smith E","year":"2010","unstructured":"Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010, 121:1746-55. 10.1161\/CIRCULATIONAHA.109.924886","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.07.152","article-title":"Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice","volume":"388","author":"van Es T","year":"2009","unstructured":"van Es T, van Puijvelde GH, Ramos OH, et al.. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009, 388:261-5. 10.1016\/j.bbrc.2009.07.152","journal-title":"Biochem Biophys Res Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01308.x","article-title":"A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis","volume":"20","author":"Armstrong AW","year":"2011","unstructured":"Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011, 20:544-9. 10.1111\/j.1600-0625.2011.01308.x","journal-title":"Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.040","article-title":"Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis","volume":"79","author":"Lockshin B","year":"2018","unstructured":"Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018, 79:345-52. 10.1016\/j.jaad.2018.02.040","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.009","article-title":"The Th17\/Treg imbalance in patients with acute coronary syndrome","volume":"127","author":"Cheng X","year":"2008","unstructured":"Cheng X, Yu X, Ding YJ, et al.. The Th17\/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008, 127:89-97. 10.1016\/j.clim.2008.01.009","journal-title":"Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon T","year":"2013","unstructured":"Simon T, Taleb S, Danchin N, et al.. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013, 34:570-7. 10.1093\/eurheartj\/ehs263","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles","volume":"35","author":"Taleb S","year":"2015","unstructured":"Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015, 35:258-64. 10.1161\/ATVBAHA.114.303567","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut E","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, et al.. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019, 139:1054-62. 10.1016\/j.jid.2018.10.042","journal-title":"J Invest Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-s)","volume":"140","author":"Gelfand JM","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, et al.. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-s). J Invest Dermatol. 2020, 140:1784-1793.e2. 10.1016\/j.jid.2020.01.025","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan W","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZ, Warren RB, Griffiths CE, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017, 176:890-901. 10.1111\/bjd.14964","journal-title":"Br J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan C","year":"2011","unstructured":"Ryan C, Leonardi CL, Krueger JG, et al.. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011, 306:864-71. 10.1001\/jama.2011.1211","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos T","year":"2013","unstructured":"Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013, 27:622-7. 10.1111\/j.1468-3083.2012.04500.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000763","article-title":"Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials","volume":"5","author":"Champs B","year":"2019","unstructured":"Champs B, Degbo\u00e9 Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open. 2019, 5:e000763. 10.1136\/rmdopen-2018-000763","journal-title":"RMD Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref24","unstructured":"Assessing Risk of Bias in Included Studies. (2017). Accessed. August 1, 2020: http:\/\/1.cochrane.org\/chapter_8\/8_assessing_risk_of_bias_in_included_studies.htm."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3353","article-title":"Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial","volume":"100","author":"Guenther L","year":"2020","unstructured":"Guenther L, Potts Bleakman A, Weisman J, et al.. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol. 2020, 100:adv00006. 10.2340\/00015555-3353","journal-title":"Acta Derm Venereol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling M","year":"2017","unstructured":"Sticherling M, Mrowietz U, Augustin M, et al.. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017, 177:1024-32. 10.1111\/bjd.15707","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi C","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, et al.. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012, 366:1190-9. 10.1056\/NEJMoa1109997","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"182","author":"Reich K","year":"2020","unstructured":"Reich K, Augustin M, Tha\u00e7i D, et al.. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2020, 182:869-79. 10.1111\/bjd.18384","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel J","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A, et al.. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017, 77:667-74. 10.1016\/j.jaad.2017.05.033","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran V","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, et al.. Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020, 59:2774-84. 10.1093\/rheumatology\/kez684","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab628","article-title":"Response to secukinumab on synovitis using power Doppler ultrasound in psoriatic arthritis: 12-week results from a Phase III study, ultimate","volume":"61","author":"D'Agostino MA","year":"2022","unstructured":"D'Agostino MA, Schett G, L\u00f3pez-Rdz A, et al.. Response to secukinumab on synovitis using power Doppler ultrasound in psoriatic arthritis: 12-week results from a Phase III study, ultimate. Rheumatology (Oxford). 2022, 61:1867-76. 10.1093\/rheumatology\/keab628","journal-title":"Rheumatology (Oxford)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos X","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, et al.. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021, 80:582-90. 10.1136\/annrheumdis-2020-218808","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210912","article-title":"Secukinumab in United States biologic-na\u00efve patients with psoriatic arthritis: results from the randomized, placebo-controlled choice study","volume":"49","author":"Nguyen T","year":"2022","unstructured":"Nguyen T, Churchill M, Levin R, et al.. Secukinumab in United States biologic-na\u00efve patients with psoriatic arthritis: results from the randomized, placebo-controlled choice study. J Rheumatol. 2022, 49:894-902. 10.3899\/jrheum.210912","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.827618","article-title":"Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells","volume":"119","author":"Eid RE","year":"2009","unstructured":"Eid RE, Rao DA, Zhou J, et al.. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009, 119:1424-32. 10.1161\/CIRCULATIONAHA.108.827618","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.690081","article-title":"Interleukin-17A promotes aortic endothelial cell activation via transcriptionally and post-translationally activating p38 mitogen-activated protein kinase (MAPK) pathway","volume":"291","author":"Mai J","year":"2016","unstructured":"Mai J, Nanayakkara G, Lopez-Pastrana J, et al.. Interleukin-17A promotes aortic endothelial cell activation via transcriptionally and post-translationally activating p38 mitogen-activated protein kinase (MAPK) pathway. J Biol Chem. 2016, 291:4939-54. 10.1074\/jbc.M115.690081","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of Interleukin 17 on the cardiovascular system","volume":"16","author":"Robert M","year":"2017","unstructured":"Robert M, Miossec P. Effects of Interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017, 16:984-91. 10.1016\/j.autrev.2017.07.009","journal-title":"Autoimmun Rev"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale DJ","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet Lond Engl. 2018, 391:2273-84. 10.1016\/S0140-6736(18)30830-4","journal-title":"Lancet Lond Engl"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.027","article-title":"Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"79","author":"Loos AM","year":"2018","unstructured":"Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2018, 79:135-44.e7. 10.1016\/j.jaad.2018.02.027","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh JA","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al.. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019, 71:5-32. 10.1002\/art.40726","journal-title":"Arthritis Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec L","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al.. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020, 79:700-12. 10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp KA","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al.. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018, 79:277-86.e10. 10.1016\/j.jaad.2018.03.037","journal-title":"J Am Acad Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin CT","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, et al.. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet Lond Engl. 2020, 395:427-40. 10.1016\/S0140-6736(19)33161-7","journal-title":"Lancet Lond Engl"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190116","article-title":"Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis","volume":"47","author":"Deodhar A","year":"2020","unstructured":"Deodhar A, Gladman DD, McInnes IB, et al.. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2020, 47:539-47. 10.3899\/jrheum.190116","journal-title":"J Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14125","article-title":"Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials","volume":"31","author":"Wu D","year":"2017","unstructured":"Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N. Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2017, 31:992-1003. 10.1111\/jdv.14125","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1023\/b:ejep.0000020447.59150.f9","article-title":"Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients","volume":"19","author":"Mallbris L","year":"2004","unstructured":"Mallbris L, Akre O, Granath F, Yin L, Lindel\u00f6f B, Ekbom A, St\u00e5hle-B\u00e4ckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004, 19:225-30. 10.1023\/b:ejep.0000020447.59150.f9","journal-title":"Eur J Epidemiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201497","article-title":"The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone","volume":"72","author":"Eder L","year":"2013","unstructured":"Eder L, Jayakar J, Shanmugarajah S, et al.. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013, 72:715-20. 10.1136\/annrheumdis-2012-201497","journal-title":"Ann Rheum Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink","volume":"135","author":"Parisi R","year":"2015","unstructured":"Parisi R, Rutter MK, Lunt M, Young HS, Symmons DP, Griffiths CE, Ashcroft DM. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015, 135:2189-97. 10.1038\/jid.2015.87","journal-title":"J Invest Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted JA","year":"2011","unstructured":"Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011, 63:1729-35. 10.1002\/acr.20627","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0052-6","article-title":"Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors","volume":"15","author":"Famenini S","year":"2014","unstructured":"Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014, 15:45-50. 10.1007\/s40257-013-0052-6","journal-title":"Am J Clin Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1254145","article-title":"The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study","volume":"29","author":"Shaaban D","year":"2018","unstructured":"Shaaban D, Al-Mutairi N. The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study. J Dermatolog Treat. 2018, 29:3-7. 10.1080\/09546634.2016.1254145","journal-title":"J Dermatolog Treat"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker PM","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, et al.. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019, 380:752-62. 10.1056\/NEJMoa1809798","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205854-the-impact-of-interleukin-17-inhibitors-on-major-adverse-cardiovascular-events-in-psoriasis-or-psoriatic-arthritis-patients-naive-to-biologic-agents-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:14:47Z","timestamp":1716534887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205854-the-impact-of-interleukin-17-inhibitors-on-major-adverse-cardiovascular-events-in-psoriasis-or-psoriatic-arthritis-patients-naive-to-biologic-agents-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.60980","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}